Nicholas Jacobus

Gilead Sciences partners with PEPFAR to enhance access to Lenacapavir for HIV prevention, aiming to support over 2 million people in resource-limited countries.

BioNTech's BNT323 shows promise in slowing breast cancer progression, boosting shares and paving the way for new treatment options.

In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major pharmaceutical layoffs shaping 2025, and cover Pfizer’s response to political pressure on COVID-19 vaccine safety evidence.

Radiance Biopharma partners with Novatim to advance RB-601, a promising bispecific nanobody ADC targeting key cancer drivers for solid tumors.

In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into the evolving GLP-1 market, and Sanofi’s share decline following disappointing Phase III results for Amlitelimab.

Sanofi's stock plummets over 10% as Amlitelimab's Phase III trial results raise concerns about the company's future pipeline and Dupixent's patent expiration.

SeqOne's acquisition of Congenica enhances its AI-driven genomic solutions, expanding global reach and transforming genetic data analysis for personalized medicine.

Novo Nordisk reveals Wegovy's 57% greater risk reduction for heart attack and stroke compared to Tirzepatide in obese patients at ESC Congress.

Pharmaceutical Executive Daily highlights Pfizer's defense of vaccine data integrity, insights on GLP-1 investments, and Novartis' $5.2 billion acquisition of Argo Biopharmaceuticals.

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using War-Lock technology, enhancing treatment options.

Argo Biopharmaceuticals partners with Novartis to advance innovative siRNA therapies for cardiovascular diseases, enhancing treatment options and patient outcomes.

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their unique OdyssION drug discovery platform.

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and safety in care.

Johnson and Johnson halts Nipocalimab's development for rheumatoid arthritis after Phase 2a trial shows no significant benefits over existing therapies.

The blood purification technology is used for the treatment of severe treatment-refectory systematic lupus erythematosus (SLE).

Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about leveraging point-of-care marketing momentum and its influence on decision making and how does Doceree maintain contextual relevance in marketing on a national scale.

Outlook Therapeutics faces FDA hurdles for Lytenava's approval in wet AMD, seeking clarity on efficacy requirements while expanding globally.

Doctor Harshit Jain, Founder and Global CEO of Doceree, spoke with Pharmaceutical Executive about the role of AI in programmatic marketing, and the expectations of developments in communication between healthcare professionals and pharmaceutical brands.

Replicate Bioscience partners with Novo Nordisk to advance self-replicating RNA therapies for obesity and type 2 diabetes, enhancing innovative treatment options.

Amylyx Pharmaceuticals halts Amx0035's Orion program for PSP, shifting focus to Avexitide and other promising treatments for neurodegenerative diseases.

Bayer's Gadoquatrane, a low-dose MRI contrast agent, aims to enhance imaging safety and efficacy for chronic disease patients, pending FDA approval.

ACOG reaffirms support for COVID-19 vaccines during pregnancy, challenging recent CDC recommendations and emphasizing maternal and fetal health.

Pfizer initiates layoffs at its Bothell site as part of a broader cost-cutting strategy, aiming to enhance R&D efficiency and automation.

Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic improvements in the Phase III Attain-2 trial, paving the way for global regulatory submissions.

Genentech broke ground on a $700 million manufacturing facility in Holly Springs, North Carolina its first on the U.S. East Coast supporting next-generation obesity treatments and metabolic medicines as part of Roche’s broader $50 billion U.S. investment in innovation, job creation, and advanced biomanufacturing.

The CDC appointed Retsef Levi, a vocal critic of mRNA Covid-19 vaccines, to lead its Covid-19 immunization workgroup, a panel tasked with reviewing vaccine safety and effectiveness, despite controversy surrounding his past calls for vaccine withdrawal.

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of Imdelltra, securing an $885 million upfront payment and potential additional royalties, while retaining rights to other pipeline assets and future high-sales milestones.

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple hospitalizations, and deaths linked to chikungunya-like illness.

Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 clinical trial of LHP588, a novel gingipain inhibitor targeting Porphyromonas Gingivalis, aimed at slowing Alzheimer's progression in infected patients by addressing a potential microbial cause of neuroinflammation and neurodegeneration

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea HD due to a major amendment stemming from a third-party manufacturing inspection. Despite the delay, Eylea HD remains available in the U.S., and Regeneron anticipates a swift resolution as they address manufacturing concerns and continue expanding treatment options.